PFM Health Sciences’s Intellia Therapeutics NTLA Stock Holding History

PFM Health Sciences’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-344,868	Closed	-$19.3M	–	94
2022 Q3	$19.3M	Buy	344,868 +181,588	+111%	+$11.3M	0.7%	53
2022 Q2	$8.45M	Sell	163,280 -124,629	-43%	-$6.33M	0.32%	63
2022 Q1	$20.9M	Buy	287,909 +109,687	+62%	+$9.29M	0.78%	45
2021 Q4	$21.1M	Hold	178,222	–	–	0.72%	48
2021 Q3	$23.9M	Hold	178,222	–	–	0.7%	48
2021 Q2	$28.9M	Sell	178,222 -105,879	-37%	-$8.24M	0.9%	42
2021 Q1	$22.8M	Buy	+284,101	New	+$19.1M	0.7%	49

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

PFM Health Sciences's NTLA Position: Q4 2022 in Review

PFM Health Sciences sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 344,868 shares — an estimated $19.3M sold.

PFM Health Sciences first reported a position in NTLA in Q1 2021 and held it in 7 quarters. The position peaked at $28.9M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

PFM Health Sciences reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
PFM Health Sciences sold 344,868 Intellia Therapeutics shares in Q4 2022, an estimated $19.3M.
PFM Health Sciences first reported a position in Intellia Therapeutics in Q1 2021 and held it in 7 quarters.
PFM Health Sciences's Intellia Therapeutics position peaked at $28.9M in Q2 2021.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on PFM Health Sciences's 13F filing for Q4 2022, filed 14 Feb 2023.